



Review article

Treatment of Thyroid Follicular Carcinoma[☆]Antonio Ríos,^{*} José M. Rodríguez, Pascual Parrilla

Unidad de Cirugía Endocrina, Servicio de Cirugía General y del Aparato Digestivo I, Instituto Murciano de Investigación Biosanitaria (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain

ARTICLE INFO

Article history:

Received 24 January 2015

Accepted 3 June 2015

Available online 27 November 2015

Keywords:

Follicular carcinoma

Thyroid

Invasion

Differentiation

Minimally invasive

Invasive

Surgery

¹³¹I ablation

A B S T R A C T

Differentiated thyroid carcinoma includes 2 different tumour types, papillary (PC) and follicular carcinoma (FC), and although similar, their prognosis is different. FC is uncommon, and this has led to it often being analysed together with PC, and therefore the true reality of this tumour is difficult to know. As a result, the diagnostic and therapeutic management and the prognostic factors in differentiated carcinoma are more predictive of PC than FC. In this review we analyse the current state of many of the therapeutic aspects of this pathology. The best surgical technique and the usefulness of associated lymphadenectomy is also analysed. Regarding post-surgical ablation with ¹³¹I, the indications, doses and usefulness are discussed. For the remaining therapies we analyse the few indications for radiotherapy and chemotherapy, and of new drugs such as tyrosine kinase inhibitors.

© 2015 AEC. Published by Elsevier España, S.L.U. All rights reserved.

Palabras clave:

Carcinoma folicular

Tiroides

Invasión

Diferenciación

Mínimamente invasivo

Ampliamente invasivo

Cirugía

Ablación con ¹³¹I

Tratamiento del carcinoma folicular de tiroides

R E S U M E N

El carcinoma diferenciado de tiroides incluye 2 tipos tumorales diferentes: el carcinoma papilar (CP) y el folicular (CF) y, aunque similares, su pronóstico es diferente. La infrecuencia del CF ha hecho que habitualmente se analice conjuntamente con el CP, lo cual dificulta conocer su verdadera realidad. En esta revisión se analiza la situación de los diferentes aspectos terapéuticos de esta dolencia. Se revisa cuál es la mejor técnica quirúrgica y la utilidad de realizar vaciamiento ganglionar asociado. Respecto a la ablación posquirúrgica con ¹³¹I se evalúan las indicaciones, las dosis y su utilidad. En el resto de terapias se analizan las pocas indicaciones que tiene la radioterapia y la quimioterapia, y la aparición de nuevos fármacos como los inhibidores de la tirosin-kinasa.

© 2015 AEC. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

[☆] Please cite this article as: Ríos A, Rodríguez JM, Parrilla P. Tratamiento del carcinoma folicular de tiroides. Cir Esp. 2015;93:611-618.

^{*} Corresponding author.

E-mail address: arzrios@um.es (A. Ríos).

Introduction

Differentiated carcinoma is the most common thyroid tumour, and in the majority of cases it is associated with a favourable prognosis.¹ The denomination of differentiated carcinoma covers two tumour types with very different pathogenesis, biology and clinical behaviour. The current tendency is to consider them as different entities. These two tumours are papillary carcinoma (PC) and follicular carcinoma (FC), which although similar have different prognoses. Thus FC is more vascularised and usually presents a higher rate of vascular invasion and clinical aggressiveness.¹

The incidence of FC is strongly related with iodine deficit, and it is decreasing due to iodine supplementation.^{1,2} Although there are major variations between populations, its incidence is estimated to stand at 1–2 cases for every 100 000 women/year, and around 0.4–0.5 cases for every 100 000 men/year. This rareness has led to its usually being analysed together with PC, hindering knowledge of the true nature of the former.¹ Thus the majority of studies analysing the usefulness of certain diagnostic tests, the therapeutic efficacy of different treatments and which prognostic factors are the most significant for differentiated carcinoma, as the series include more PC than FC, their results are more predictive and useful for PC than they are for FC.³ Few studies contain a sufficient number of FC cases to allow it to be studied independently, and the results of these studies are not consistent.^{3–5}

The treatment of FC currently depends on tumour extension. Thus patients with greater extension or a higher risk of recurrence are treated more aggressively and monitored more closely. However, in localised low risk tumours a more conservative treatment is equally effective.¹ Additionally, the different subtypes of FC have to be taken into account, as they directly influence patient prognosis (Table 1).

Many controversies surround the diagnosis, treatment and evolution of FC. This revision aims to analyse the current state of the different therapeutic options for FC and determine which is the best medical and surgical treatment for this group of patients, based on the scientific evidence.

To this end two bibliographical searches were performed. On the one hand scientific publications indexed in the different databases (Pubmed, Embase and Conchrane Library) and, on the other, the guides and consensus documents of different Spanish, European and American scientific societies on the treatment of FC.

Controversies in the Surgical Treatment of Follicular Carcinoma

The Utility of Molecular Cytological Markers in Preoperative Diagnosis and Surgical Planning

Fine needle aspiration (FNA) is currently the gold standard for differential diagnosis between a benign nodule and thyroid cancer, and its sensitivity largely depends on the cytologist's experience.^{1,6} Nevertheless, the main problem with this technique is its lack of sensitivity in the evaluation of follicular neoplasia, as it is unable to distinguish between benign lesions (follicular adenoma) and malignant entities (thyroid follicular carcinoma and the follicular variant of papillary carcinoma),^{1,7} given that it is no longer possible to diagnose vascular or capsular invasion.^{1,8} To improve the diagnostic sensitivity of FNA in follicular neoplasia, immunohistochemical and molecular diagnosis techniques are being analysed. Several molecules have therefore been said to be involved in the carcinogenic process, and they have been proposed as thyroid malignancy markers to increase the diagnostic precision of FNA. They include telomerase, thyroperoxidase, keratan-sulphate, the group of high mobility proteins I (Y) (HMGI[Y]), the cell surface mesothelial antigen HBME-1, thyroperoxidase, cytokeratin 19 and galectin-3 (GAL3).^{9,10} Several gene expressions are also being analysed, and the expression of more than 100 genes has been detected.¹¹ It should be pointed out that the fusion of oncogene PAX8/peroxidase proliferator- γ receptor (PPAR γ) has been identified in approximately 25%–50% of FC, with a translocation between regions 3p25 and 2q13.

Although advances are occurring very quickly, the results on the utility of the different proposed malignancy markers often disagree.^{12–15} Some studies have shown that, in comparison with using markers in isolation, a sequential combination of two markers is more useful. The combination of GAL3 and HBME-1, or GAL3 and cytokeratin 19 in the case of oncocytic lesions therefore improve the diagnostic sensitivity of FNA.^{12,14} Cytological markers are not currently in widespread use.

Lastly, although analysis of the BRAF (V600E) mutation has been shown to be of use in selecting nodules with indeterminate cytology (AUS/FLUS), it is highly specific for PC and not FC, so that it is not useful for the diagnosis of FC.^{16–19} However, the RAS mutation may be important in the identification of the follicular variant of PC and even FC, although more studies are required to confirm these preliminary results.^{20,21}

Which is the Best Initial Surgery for Follicular Carcinoma?

The main problem which tends to arise when considering surgery for FC is that the operation is usually indicated by the diagnosis of follicular neoplasia, but without knowing that it is a carcinoma. This means that the definitive diagnosis of FC usually takes place after the patient has been operated on. Due to this, we have a patient diagnosed with FC who has usually already been subjected to a hemithyroidectomy. There is now consensus and it is accepted that hemithyroidectomy is the correct surgery in only 2 cases: (1) microcarcinoma (tumour <1 cm) that is unifocal with no vascular invasion or

Table 1 – Histological Types of Thyroid Follicular Carcinoma.

Variants	Incidence %
Classic follicular carcinoma	83–90
Minimally invasive, not angioinvasive	
Minimally invasive, angioinvasive	
Widely invasive	
Hürthle cell carcinoma	2–6
Insular or poor differentiated carcinoma	10
Clear cell variant carcinoma	<1

prior exposure to radiation, and (2) minimally invasive FC smaller than 3–4 cm without vascular invasion.^{2,22}

In the other cases, the majority of studies indicate that lobectomy is an independent factor which affects tumour recurrence, so that it is recommended that the thyroidectomy be completed if it was not complete in the first operation.²³ However, depending on the size of the remaining thyroid, when the risk of disease persistence is low, and an effective option to completing the thyroidectomy is radioiodine ablation.²⁴ In cases where an entire lobe has been left, ¹³¹I is not recommended, due to its low efficacy in these cases. Moreover, completing the thyroidectomy has low complication rates when it is performed by experienced surgeons, facilitating post-surgical ablation using ¹³¹I and permitting a more suitable follow-up.²⁵ Some authors accept almost total thyroidectomy or Dunhill's technique, although this gives rise to the problem that the thyroid remnant will hinder the evaluation of possible relapses at a cervical level and ablation with ¹³¹I.^{1,2}

How much time should pass between the first surgery and complete thyroidectomy is a controversial question. Although there is no consensus, Glockzin et al.,²⁶ in a series of 128 thyroid carcinomas re-operated to complete the thyroidectomy, state that there is less morbidity when at least 3 months have elapsed since the first surgery.

The Utility of Intraoperative Biopsy

Given that the majority of FC patients are operated with the diagnosis of follicular neoplasia,^{2,27} intraoperative biopsy (IOB) has the purpose of deciding the definitive surgical procedure during the first operation, avoiding the need for a second operation as well as unnecessarily aggressive surgery.⁴ However, although some authors have described its utility,²⁸ the majority show that it is not a cost-efficient technique for the diagnosis of FC.^{29,30} Hamburger and Hamburger³¹ therefore state that only 3 of 359 IOB (0.8%) contributed to the decision on surgical treatment, while Shaha et al.³² show similar limitations. It also has to be said that there are problems with the reproducibility of results due to differences in interpretation between observers and the same observer in histopathological diagnosis.³³ Although it is not accepted by the majority of pathologists, IOB has also been said to have the drawback of the deterioration in the surgical specimen resected due to freezing, which may affect its subsequent study in paraffin.

As there are no randomised prospective studies (the only one that exists indicates a low level of utility²⁹), the tendency is to cease using IOB routinely for follicular neoplasias (Bethesda III and IV).³⁴ Some authors state that IOB should be reserved for cases in which surgical exploration gives rise to the suspicion of a carcinoma.^{29,30,34} Lastly, it should be pointed out that although some groups found no false positives, they did detect a high percentage of false negatives, so that they continue to recommend IOB as it prevents a repeat operation in a group of patients.

The lack of sensitivity of IOB in thyroid follicular neoplasias could theoretically be improved by using molecular techniques (see Introduction), although studies would be required to confirm this.

The Type of Node Dissection to be Used

Unlike PC, FC usually has less of a tendency to spread into the lymphatic system. Thus removal of the ganglia either before or during the operation is indicated if lymphatic involvement is suspected.³⁵ The benefits of prophylactic central dissection are arguable, as there is no evidence that this improves the relapse or mortality rates, and it increases postoperative morbidity.^{1,2} Nevertheless, it does permit greater precision in disease staging.

The Most Appropriate Surgery for Minimally Invasive Carcinomas

Although total thyroidectomy is recommended in FC, minimally invasive carcinoma is the least aggressive FC and it may be treated by hemithyroidectomy.^{5,36} Although there is no consensus on size, in cases when it attains a size larger than 3–4 cm it is advised that thyroidectomy be completed on the contralateral side (Table 2).

The latest classifications take into account not only whether FC are minimally or widely invasive, but also consider angioinvasion. Thus minimally invasive FC is classified into types with and without angioinvasion (Table 1). This is important because angioinvasive types have a poorer prognosis and require more aggressive treatment.³⁷

More Aggressive Variants of Follicular Carcinoma

Hürthle cell or oncocytic carcinoma has a higher rate of multicentricity and metastatic dissemination, above all in the cervical lymph nodes (25% of cases), although it also spreads to other organs. Given this greater presence of lymph node involvement and the fact that these tumours take up little iodine (so that radioiodine ablation is less effective), lymphatic surgery is the classical recommendation as performed in PC, advising ipsilateral central dissection.

However, there is no consensus and, in spite of the description of a higher risk, some institutions such as the College of American Pathologists state that the biological behaviour of Hürthle's carcinoma depends more on the size and extension of the tumour than it does on its histology. They therefore consider it to be a variant of FC with a similar prognosis, and believe that it should be treated in the same way as the equivalent stage of non-Hürthle cell FC.^{38,39}

The insular or poorly differentiated type is usually located in the sinus of a multinodular goitre. It is characterised by intermediate morphology and behaviour between differentiated carcinomas and anaplastic carcinoma. The clinical profile corresponds to women over the age of 50 years old who present rapid growth of a pre-existing thyroid lesion. It is characterised by high metastatic power and a high relapse rate, while metastasis to lymph nodes, the lungs and bones is often found at diagnosis. The majority of patients die within the first 3 years after diagnosis. The prognosis depends on the initial TNM classification, whether surgery was complete and if it responded to treatment with radioactive iodine.⁴⁰

Lastly, the clear cell variant is more aggressive, although it is also rare. Clear cell follicular carcinoma with metaplastic changes and a mitochondrial formation of intracytoplasmic

vesicles, glycogen and fat accumulation and thyroglobulin deposits. The majority of primitive clear cell tumours present histologically as microfollicular or trabecular.

In all of these more aggressive variants surgical treatment must also be more aggressive.

The Most Appropriate Surgery for Locally Advanced Carcinoma

Cervical structure invasion is rare but increases the possibility of complications that compromise the patient's life and limit the utility of non-surgical therapies. Due to this, in the absence of uncontrolled disseminated disease, the possibility of surgical resection has to be evaluated.⁴¹ The indication for surgery depends not only on local resectability but also on the individual condition of the patient. Depending on the extension of the invasion, the technique used may vary from simple tracheal up to complex laryngotracheal or oesophageal resection.⁴

Although there is no consensus on the optimum surgery for carcinoma with laryngotracheal invasion, aggressive resection is generally recommended to reduce morbidity and maintain the integrity of the airway.⁴¹ Residual macroscopic disease has an unfavourable affect on evolution, above all in young patients.

Which Surgical Option is the Best for Distant Metastasis

The best therapeutic option for distant metastasis of FC is resection, whenever it is accessible.^{42,43} This treatment must be completed, or sometimes treated only with ¹³¹I, whenever they are iodine-absorbing. In the other cases and in cases that are refractory to ¹³¹I treatment, the best therapeutic option is local radiotherapy.^{42,43} As a general rule these patients need a multidisciplinary therapeutic approach, as they usually require surgical resection, ablation with ¹³¹I, radiotherapy and sometimes chemotherapy to control or relieve the symptoms.^{42,44}

Controversies in the Ablation of Residual Post-Surgical Thyroid Tissue Using Radioactive Iodine

When Should Ablation Using Radioactive Iodine Be Indicated?

Ablation using ¹³¹I makes it possible to destroy thyroid remnants that may remain in the thyroid bed, reducing relapses and facilitating the monitoring of thyroglobulin.^{24,45,46}

The systematic use of ¹³¹I is accepted in those FC cases with persistent disease, vascular invasion and factors leading to a poor prognosis, as it reduces the relapse rate. Nevertheless, in unifocal microcarcinomas and in non-angioinvasive minimally invasive carcinomas it has not been proven to have any benefit, so that ablation is not recommended in these cases. In other cases which do not have a poor prognosis but are neither unifocal microcarcinomas nor minimally invasive, there is no consensus on its utility, as its benefits are controversial.

What Is the Most Effective Dose of ¹³¹I?

The dose of ¹³¹I to be used may vary depending on several factors. To use low doses of ¹³¹I, from 30 to 50 mCi, it is

fundamental that any remnant be small or non-existent, evaluated by total body gammagraphy and using 2-3 mCi ¹³¹I.⁴⁷ The dose of 30 mCi became quite popular as it was a way of avoiding hospitalisation. Although this is not the case in all countries, currently it is possible to carry out ablation with ¹³¹I on an out-patient basis, with a dose of up to 60 mCi, given that those who are close to the patient are exposed to a minimum amount of radiation.

It is important to select the correct dose, as several authors state that the success rates of ablation increase with the dose of ¹³¹I, although some of them find the differences between doses to be minimal.^{24,47} Thus in a randomised study Johansen K et al.⁴⁸ show that the ablation index with 30 mCi stands at 81%, as opposed to 84% with 100 mCi. Nevertheless, another randomised study⁴⁹ shows that with 30 mCi the complete ablation index is 63%, with 50 mCi it is 78%, with 90 mCi it is 74% and with 155 mCi it is 77%. Recently, Schlumberger et al.⁵⁰ in a phase 3 randomised study, showed that in low risk patients treatment with low dose ¹³¹I (30 mCi) is effective. Likewise, the clinical trial by Mallick et al.⁵¹ shows that the dose of 30 mCi may be as effective as a 100 mCi dose (85% versus 88.9% of complete ablation, respectively).

What Is the Therapeutic Impact of Ablation With ¹³¹I?

There is much discrepancy about the results of ablation using ¹³¹I, although the majority of authors mention lower rates of relapse and mortality afterwards. Another factor that may justify these differences is the extension of the thyroidectomy performed, as it is not homogeneous in all cases.^{1,2}

Table 2 – Classification of the Drugs Which Are Potentially Useful in Follicular Carcinoma.

Type of Chemotherapy	Groups	Main Active Ingredients
Classic cytotoxic chemotherapy		Doxorubicin Cisplatin Vinblastin Adriamycin
Redifferentiating agents	Retinols	All-trans-retinoic acid Isotretinoin
	PPAR γ agonists Histone deacetylase inhibitor	Rosiglitazone Valproic acid Butyric acid Trichostatin A, suberanilohydroxamic acid (SAHA) Desipeptide
Multikinase inhibitors	Inverse transcriptase inhibitors Motesanib	Nevirapin Efavirenz
	Sorafenib Axitinib Vandetanib Sunitinib	

There is sufficient scientific evidence to indicate that in high-risk tumours carcinoma recurrence, distant recurrence and deaths due to cancer are significantly less after ablation with radioiodine ^{131}I than is the case with L-T4 or only medical treatment.^{1,2}

The Utility of Other Treatments

Is Treatment With Thyroid Hormone Useful to Obtain TSH Suppression?

The theoretical aim of TSH suppressive therapy with L-T4 is to inhibit the growth, which requires TSH, of the thyroid tissue that may remain following the initial treatment. Some authors state that rates of recurrence fall with treatment using L-thyroxin,⁵² although the optimum level of TSH required is still unknown. Initially the dose of L-T4 should be sufficient to reduce levels of TSH to ≤ 0.1 mU/l, as there is no evidence that suppression of TSH below this level improves results.

The retrospective study by Pujol et al.⁵³ shows that disease-free survival increases when TSH is constantly suppressed (TSH < 0.05 U/ml), while the degree of TSH suppression is an independent predictor of recurrence. However, a prospective study with 617 patients in the National thyroid cancer treatment cooperative study found that disease stage, patient age and treatment with ^{131}I were all independent predictive factors of disease progression, while this was not so for degree of TSH suppression.⁵⁴

All of this is important, as TSH suppression to undetectable levels (subclinical thyrotoxicosis) is not innocuous, and over the long-term it may have side effects at a cardiac and bone level.⁵⁵ Thus low concentrations of TSH in serum in individuals aged 60 years old or more is associated with an increase in mortality from all causes, and in particular from circulatory and cardiovascular diseases. Due to this, in these patients TSH suppression should be avoided. During subclinical thyrotoxicosis, one aspect that should be taken into account is that the majority of patients have a prothrombotic profile. TSH suppression is therefore unnecessary in patients considered to be in complete remission after a suitable follow-up period, so that therapy can be switched from suppression to replacement. TSH suppressive therapy should be indicated for patients with evidence of persistent disease. Additionally, in high-risk patients who have undergone remission, suppressive therapy is advised during 3–5 years.⁵⁶

Radiotherapy in Follicular Carcinoma?

External radiotherapy of the neck is rarely used, and it is usually indicated for tumours or recurrent tumours that cannot be resected, above all if they do not absorb ^{131}I . External radiotherapy is also indicated for bone and brain metastasis.⁵⁷ In cases of microscopically invasive FC a higher disease-free rate was described when radiotherapy was used in comparison with when it was not (53% versus 38%).⁵⁸

The fact that radiotherapy requires careful planning must be taken into account, with precautions to prevent

post-radiation myelopathy.⁴ For residual microscopic disease a total dose of 50–60 Gy must be given for the neck and upper mediastinum, in 25–30 sessions with 5 sessions per week. An increase of 5–10 Gy may be given if there is a large residual neoplastic centre.

Is Chemotherapy of Any Use Now?

Classical Cytotoxic Chemotherapy

Cytotoxic chemotherapy is of no utility in the treatment of FC. Its use is restricted to patients with disease that progresses in spite of surgery, ^{131}I or other forms of treatment.^{4,59} The response is poor, so much so that the best response is only 10%–20% with the use of doxorubicin or a combination of doxorubicin–cisplatin. However, recently vinblastin with or without adriamycin seems to improve results.⁵⁹ In any case, responses are partial and transitory, without any clear lengthening of survival.

The response to chemotherapy seems to be better in poorly differentiated carcinomas, although this requires confirmation by more studies.⁶⁰ In advanced cases, chemotherapy before surgery may sometimes be effective in reducing tumour size and aiding surgery.⁵⁹

Redifferentiating Agents

These agents have the purpose of redifferentiating those cases which have become dedifferentiated so that they absorb ^{131}I , so that ^{131}I can be used again as a therapy. Several substances have been used for this, with varying results. The retinoids are the group that has been studied the most, and existing clinical studies indicate that treatment using them is tolerated well, and that absorption of ^{131}I increased by from 20% to 50%.^{61,62} In these cases thyroglobulin usually increases as a sign of tumour redifferentiation. Several studies are planned to evaluate which advanced thyroid cancer patient subgroups could benefit from its use. Another group of substances are the PPAR γ agonists, although few studies show that they slightly increase the absorption of radioiodine and that they are well-tolerated. Histone deacetylase inhibitors inhibit cellular proliferation and permit dedifferentiation, although clinical studies to confirm their utility are lacking. Lastly, the use of reverse transcriptase inhibitors (nevirapin and efavirenz) was described recently in cancer, although these treatments are usually used for HIV. Nevertheless, given their toxicity it is not recommended that they be used until their efficacy has been proven.

Drugs That Inhibit the Intracellular Proliferation Cascade

Other molecular therapies and antiangiogenic agents are being analysed and may represent an aid for some patients,⁶³ although these studies are only preliminary. Several clinical trials are therefore evaluating tyrosin-kinase and angiogenesis inhibitors in the treatment of patients with metastatic disease or differentiated carcinomas that are refractory to other treatments. Although the results are hopeful, they are pending confirmation in large series of patients.⁶³ Their main problem is their high percentage of side effects, which although not serious are very unpleasant (gastrointestinal symptoms, etc.).

Final Considerations

1. Molecular cytological markers are still not useful for clinical application in the preoperative diagnosis of FC.
2. The best surgical technique for FC is total thyroidectomy, except in very carefully selected cases in which hemithyroidectomy may be sufficient.
3. IOB is of limited use in ruling out FC, so that its use is not recommended.
4. Node removal in FC is only recommended when lymphatic involvement is suspected. It should not be performed as prophylaxis.
5. In minimally invasive FC it is important to differentiate between the angioinvasive and non-angioinvasive forms, as this has therapeutic and prognostic implications.
6. The non-classical variants of FC (Hürthle, insular and clear cells) have a poorer prognosis and require more aggressive initial treatment.
7. In locally advanced FC, more aggressive resection is generally recommended to reduce morbidity and maintain the integrity of the airway.
8. Ablation of thyroid tissue in FC reduces relapses and facilitates monitoring of thyroglobulin, although some groups of FC do not require ablation to achieve a good prognosis.
9. The latest clinical trials show the utility of low-dose radioiodine, facilitating the treatment of these patients on an out-patient basis. Due to this, some European groups, mostly Italian, are starting to use it in this way.
10. TSH suppression therapy improves disease-free survival, although in elderly patients and those with high cardiovascular risk it increases mortality due to cardiovascular causes.
11. External radiotherapy is indicated in relapses that cannot be resected that do not absorb ^{131}I and in brain and bone metastatic lesions.
12. Many therapeutic agents are being trialled for advanced thyroid cancer, and pharmacological gene therapy, chiefly agents that block the signalling route and redifferentiation agents, are now on the horizon as a therapeutic alternative.

Conflict of Interests

The authors declare that they have no conflict of interests.

REFERENCES

1. Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. *Med Clin North Am.* 2012;96:369-83.
2. Emerick GT, Duh QY, Siperstein AE, Burrow GN, Clark OH. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. *Cancer.* 1993;72:3287-95.
3. Ríos A, Rodríguez J, Ferri B, Martínez-Barba E, Febrero B, Parrilla P. Are prognostic scoring systems of value in patients with follicular thyroid carcinoma? *Eur J Endocrinol.* 2013;169:821-7.
4. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol.* 2006;154:787-803.
5. Lo CY, Chan WF, Lam KY, Wan KY. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. *Ann Surg.* 2005;242:708-15.
6. Jogai S, Al-Jassar A, Temmim L, Dey P, Adesina AO, Amanguno HG. Fine needle aspiration cytology of the thyroid: a cytohistologic study with evaluation of discordant cases. *Acta Cytol.* 2005;49:483-8.
7. Carling T, Udelsman R. Follicular neoplasms of the thyroid: what to recommend. *Thyroid.* 2005;15:583-7.
8. Lew JI, Snyder RA, Sanchez YM, Solorzano CC. Fine needle aspiration of the thyroid: correlation with final histopathology in a surgical series of 797 patients. *J Am Coll Surg.* 2011;213:188-95.
9. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immuno-diagnostic method for improving preoperative diagnosis of nodular thyroid lesions. *Lancet.* 2001;357:1644-50.
10. Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. *J Exp Ther Oncol.* 2010;8:341-52.
11. Freitas BC, Cerutti JM. Genetic markers differentiating follicular thyroid carcinoma from benign lesions. *Mol Cell Endocrinol.* 2010;321:77-85.
12. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. *Endocr Relat Cancer.* 2005;12:305-17.
13. Carroll NM, Carty SE. Promising molecular techniques for discriminating among follicular thyroid neoplasms. *Surg Oncol.* 2006;15:59-64.
14. Barut F, Kandemir NO, Bektas S, Bahadır B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. *Endocr Pathol.* 2010;21:80-9.
15. Ríos A, Rodríguez JM, Galindo PJ, Montoya M, Tebar FJ, Sola J, et al. Utility of fine-needle aspiration for diagnosis of carcinoma associated with multinodular goitre. *Clin Endocrinol.* 2004;61:732-7.
16. Kim SY, Kim EK, Kwak JY, Moon HJ, Yoon JH. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation. A study based on clinical and radiologic features using a highly sensitive analytic method. *Surgery.* 2015;157:354-61.
17. Hyeon J, Ahn S, Shin JH, Oh YL. The prediction of malignant risk in the category atypia of undetermined significance/follicular lesion of undetermined significance of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results. *Cancer Cytopathol.* 2014;122:368-76.
18. Jia Y, Yu Y, Li X, Wei S, Zheng X, et al. Diagnostic value of BRAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: systematic review and meta-analysis. *Diagn Cytopathol.* 2014;42:94-101.
19. Miccoli P. Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer. *Curr Genomics.* 2014;15:184-9.
20. Eszlinger M, Piana S, Moll A, Bösenberg E, Bisagni A, Ciarrocchi A, et al. Molecular testing of thyroid fine-needle aspirations improves presurgical diagnosis and supports the histologic identification of minimally invasive follicular thyroid carcinomas. *Thyroid.* 2015;25:401-9.
21. Nikiforov YE, Otori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically

- indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *J Clin Endocrinol Metab.* 2011;96:3390-7.
22. Cooper D, Doherty G, Haugen B, Kloos R, Lee S, Mandel S, et al. Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, November 2009. The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; 2014. Available at: <http://www.thyroid.org/thyroid-guidelines/> [accessed 05.11.14]
 23. O'Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. *Eur J Surg Oncol.* 2011;37:181-5.
 24. Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels GH. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up. *Thyroid.* 2012;22:369-76.
 25. Zambudio AR, Rodríguez J, Riquelme J, Soria T, Canteras M, Parrilla P. Prospective study of postoperative complications after total thyroidectomy for multinodular goiters by surgeons with experience in endocrine surgery. *Ann Surg.* 2004;240:18-25.
 26. Glockzin G, Hornung M, Kienle K, Thelen K, Boin M, Schreyer AG, et al. Completion Thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. *World J Surg.* 2012;36:1168-73.
 27. Rios A, Rodríguez JM, Canteras M, Galindo PJ, Balsalobre MD, Parrilla P. Risk factors for malignancy in multinodular goitres. *Eur J Surg Oncol.* 2004;30:58-62.
 28. Dosen D, Turic M, Smalcelj J, Janusic R, Grgic MP, Separovic V. The value of frozen section in intraoperative surgical management of thyroid follicular carcinoma. *Head Neck.* 2003;25:521-8.
 29. Udelsman R, Westra WH, Donovan PI, Sohn TA, Carmeron JL. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. *Ann Surg.* 2001;233:716-22.
 30. LiVolsi VA, Baloch ZW. Use and abuse of frozen section in the diagnosis of follicular thyroid lesions. *Endocr Pathol.* 2005;16:285-93.
 31. Hamburger JL, Hamburger SW. Declining role of frozen section in surgical planning for thyroid nodules. *Surgery.* 1985;98:307-12.
 32. Shaha A, Gleich L, DiMaio T, Jaffe BM, et al. Accuracy and pitfalls of frozen section during thyroid surgery. *J Surg Oncol.* 1990;44:84-92.
 33. Franc B, de la Salmoniere P, Lange F, Hoany C, Louvel A, de Roquancourt A, et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. *Hum Pathol.* 2003;34:1092-100.
 34. Rios A, Rodriguez JM, Sola J, Soria T, Galindo PJ, Parrilla P. Utility of frozen-section examination for diagnosis of malignancy associated with multinodular goiter. *Thyroid.* 2004;14:600-4.
 35. Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. *Laryngoscope.* 2011;121:487-91.
 36. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, et al., German Association of Endocrine Surgeons. Diagnosis and treatment of small follicular thyroid carcinomas. *Br J Surg.* 2010;97:839-44.
 37. Dionigi G, Kraimps JL, Schmid KW, Hermann M, Sheu-Grabellus SY, de Wailly P, et al. Minimally invasive follicular thyroid cancer (MIFTC) – a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbecks Arch Surg.* 2014;399:165-84.
 38. Haigh PI, Urbach DR. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. *Surgery.* 2005;138:1152-8.
 39. Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. *J Clin Endocrinol Metab.* 2015;100:55-62.
 40. Fat I, Kulaga M, Dodis R, Carling T, Theoharis C, Rennert NJ. Insular variant of poorly differentiated thyroid carcinoma. *Endocr Pract.* 2011;17:115-21.
 41. Nishida T, Nakao K, Hashimoto T. Local control in differentiated thyroid carcinoma with extrathyroidal invasion. *Am J Surg.* 2000;179:86-91.
 42. Wexler JA. Approach to the thyroid cancer patient with bone metastases. *J Clin Endocrinol Metab.* 2011;96:2296-307.
 43. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. *J Clin Endocrinol Metab.* 2010;95:987-93.
 44. Quan GM, Pointillart V, Palussière J, Bonichon F. Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma. *Thyroid.* 2012;22:125-30.
 45. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, et al., THYRDIAG Working Group. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. *J Clin Endocrinol Metab.* 2011;96:1352-9.
 46. Sawka AM, Thepamongkhon K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2004;89:3668-76.
 47. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of ¹³¹I for remnant ablation in patients with differentiated thyroid carcinoma. *Cancer.* 1996;77:2574-80.
 48. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-¹³¹ in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. *J Nucl Med.* 1991;32:252-4.
 49. Krishnamurthy GT, Bland WH. Radioiodine I-¹³¹ therapy in the management of thyroid cancer. A prospective study. *Cancer.* 1977;40:195-202.
 50. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. *N Engl J Med.* 2012;366:1663-73.
 51. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *N Engl J Med.* 2012;366:1674-85.
 52. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med.* 1994;99:418-28.
 53. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. *J Clin Endocrinol Metab.* 1996;81:4318-23.
 54. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. *Thyroid.* 1999;8:737-44.
 55. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab.* 2005;1:32-40.
 56. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated

- thyroid carcinoma: a European perspective. *Eur J Endocrinol*. 2004;150:105-12.
57. Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson JC, et al. External beam radiotherapy in the management of differentiated thyroid cancer. *Clin Oncol*. 2003;15:337-41.
 58. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. *Int J Radiat Oncol Biol Phys*. 1988;14:1063-75.
 59. Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study. *Thyroid*. 2012;22:131-7.
 60. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2002;87:4160-5.
 61. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, et al. A clinical study of all-trans-retinoid induced differentiation therapy of advanced thyroid cancer. *Nucl Med Commun*. 2007;28:251-5.
 62. Haugen B, Larson LL, Pugazhenti U, Hays WR, Klopper JP, Kramer CA, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroidcarcinoma cell lines and predict response to treatment with retinoids. *J Clin Endocrinol Metab*. 2004;89:272-80.
 63. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience. *J Clin Endocrinol Metab*. 2010;95:2588-95.